Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ghassan M. Abushaikha has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Abdel Bayazid

    Department of Molecular, Cellular, and Developmental Biology, College of Natural Sciences and Math, University of Toledo, 2801 W. Bancroft Street, MS 601, Toledo, OH 43606, United States of America

    4 shared publications
  • Negin Abdollahi

    Department of Molecular, Cellular, and Developmental Biology, College of Natural Sciences and Math, University of Toledo, 2801 W. Bancroft Street, MS 601, Toledo, OH 43606, United States of America

    4 shared publications
  • Tyler J. Chitwood

    Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, 2801 W. Bancroft Street, MS 601, Toledo, OH 43606, United States of America

    4 shared publications
  • Abdul-Rizaq Hamoud

    Department of Neurosciences and Psychiatry, College of Medicine and Life Sciences, University of Toledo, 3000 Arlington Ave, Toledo, OH 43614, United States of America

    3 shared publications
  • Dima Sabbah

    Department of Pharmacy, Al-Zaytoonah University of Jordan, P. O. Box 130, Amman 11733, Jordan

    3 shared publications
  • Nicole Bearss

    Department of Neurosciences and Psychiatry, College of Medicine and Life Sciences, University of Toledo, 3000 Arlington Ave, Toledo, OH 43614, United States of America

    3 shared publications

Latest Publications

  • Erratum to “Development of a novel PI3Kα/CDK7 potent hybrid inhibitor for Cancer treatment” [Bioorg. Med. Chem. Lett. 140 (2026) 130738]

    by Ghassan M. Abushaikha, Tyler J. Chitwood, Abdel Bayazid, Negin Abdollahi, Chamod Maleesha Dias, Abdul-Rizaq Hamoud, Ali S. Imami, Nicole Bearss, Robert McCullumsmith, Dima Sabbah, et al.

  • Development of a novel PI3Kα/CDK7 potent hybrid inhibitor for Cancer treatment

    by Ghassan M. Abushaikha, Tyler J. Chitwood, Abdel Bayazid, Negin Abdollahi, Chamod Maleesha Dias, Abdul-Rizaq Hamoud, Ali S. Imami, Nicole Bearss, Robert McCullumsmith, Dima Sabbah, et al.

  • Open Access

    Development of a Novel PI3Kα/CDK7 Potent Hybrid Inhibitor for Cancer Treatment

    by Ghassan M. Abushaikha, Tyler J. Chitwood, Abdel Bayazid, Abdul-Rizaq Hamoud, Negin Abdollahi, Ali Sajid Imami, Nicole Bearss, Robert E. McCullumsmith, Dima Sabbah, William R. Taylor

    Phosphatidylinositol 3-kinase alpha (PI3Kα) and cyclin-dependent kinase 7 (CDK7) play key roles in the growth of multiple cancers. PI3Kα indirectly activates and enhances CDK7 expression. Our preliminary findings from screening recombinant PI3Kα on the Kinome Array showed that it may directly activate CDK7 and presents promising targets for the development of novel drugs with dual inhibition. In this work, we designed and synthesized two hybrids, HY3 and HY5, employing the strategy of combining the cores of Alpelisib and SY-5609, known selective inhibitors of PI3Kα and CDK7, respectively. HY3 showed 98% inhibition against CDK7 and 10% against PI3Kα. 10-point titration of HY3 was determined against CDK7 with an IC50 = 10.8 nM. We then developed a potent hybrid inhibitor (HY5) employing X-ray structure-based drug design. HY5 showed dual inhibition, 87% inhibition with IC50 of 87.9 nM against PI3Kα and 89% inhibition with IC50 of 638 nM against CDK7. We also screened HY5 for cytotoxicity against HCT116, SKOV3 and MCF7 cells exhibiting IC50s of 360 nM, 490 nM, and 820 nM, respectively. To compare selective killing of cancer cells, we tested HY5 against several normal cell lines: human fibroblast (WI-38), retinal pigmented epithelial cells (RPE), mouse embryonic cell line (10T1/2), and canine kidney (MDCK). HY5 was significantly less toxic against WI-38 and showed similar toxicity against 10T1/2, RPE and MDCK cells at 5, 10 and 20 μM which is comparable to the Alpelisib + SY-5609 combination. HY5 showed high selectivity for MCF7 cells where 80% were killed at 1 μM compared to only 10-50% of norm5al cells at 20 μM.

  • Open Access

    N-Benzyl-6-Chloro-4-Hydroxy-2-Quinolone-3-Carboxamides: Synthesis, Computational Studies, and Biological Investigation as Anticancer Agents

    by Sara Jamal Meknas, Eveen Al-Shalabi, Rima Hajjo, Sanaa K. Bardaweel, Ghassan Abushaikha, Kamal Sweidan, Swapnaa Balaji, Amit K. Tiwari, Haizhen A. Zhong, Dima A. Sabbah

    Cancer remains the second leading cause of death worldwide, highlighting the urgent need for novel therapeutic agents. In this work, twenty derivatives of N-benzyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamides were synthesized and spectroscopically analyzed using FT-IR, NMR (1H and 13C), and elemental analysis. Substitution of benzyl moiety with o-CH3 (8), p-OCH3 (10), m-CH3 (18), p-CH3 (19), and p-CF3 (21) demonstrated three-fold distinct cytotoxicity against human colon cancer (HCT-116) cells with IC50s of 72.0, 100.0–112.0 µM. The cheminformatics calculations disclosed that the analogues possess diverse physicochemical properties and invariable predictions across six drug-likeness scoring models, supporting their potential cytotoxicity profile against colorectal cancer cell lines (Caco-2 and HCT-116). The docking studies against both wild-type and mutant PI3Kα clarified binding interactions, implying that particular functionalities improve efficacy and selectivity. This study provides further evidence for the therapeutic promise of quinolones in targeting cancer-specific pathways and expedites the process for developing potent anticancer agents.


  • Identification and Preliminary Characterization of a Novel Tasquinimod Analog that Unexpectedly Induces Mitotic Arrest by Alteration of Microtubule Dynamics

    by Ghassan M. Abushaikha, Dewmi Rathnayake, Abdel Bayazid, Shreyas Wadwekar, Negin Abdollahi, Safiyyah Hasan, Kierra Nickelson, Isaac Kaba, Tyler J. Chitwood, William R. Taylor

    While investigating the SAR associated with tasquinimod, whose anticancer activity is primarily derived from inhibition of S100A9 and HDAC4, we designed and prepared several analogues. We identified a potent hit (FB2) that showed cytotoxicity against several cancer cells with IC50s between 0.3 and 2.0 μM. Surprisingly, FB2 appeared to halt cells during mitosis. To better define the relevance of FB2's unanticipated action, we further explored its mechanism and found that it significantly alters microtubule dynamics. KT-1 exposed to FB2 showed an elongated cellular morphology with condensed chromosomes and mitotic spindles. FB2 also reduced the rate of microtubule regrowth in cells; however, we are unable to conclude whether this is due to direct binding to tubulin or to some indirect mechanism involving initial interaction with some other target sites. These effects on tubulin dynamics are likely responsible for defects in spindle structure, mitotic arrest, and the observed robust killing of cancer cells.

  • Open Access

    Design and Synthesis of 4-O-Podophyllotoxin Sulfamate Derivatives as Potential Cytotoxic Agents

    by Ammar Bader, Majdi M. Bkhaitan, Ashraf N. Abdalla, Qasem M. A. Abdallah, Hamed I. Ali, Dima A. Sabbah, Ghadeer Albadawi, Ghassan M. Abushaikha

    4-O-Podophyllotoxin sulfamate derivatives were prepared using the natural lignan podophyllotoxin. The prepared compounds were afforded by reacting O-sulfonyl chloride podophyllotoxin with ammonia or aminoaryl/heteroaryl motif. Biological evaluation was performed in human breast cancer (MCF7), ovarian cancer (A2780), colon adenocarcinoma (HT29), and normal lung fibroblast (MRC5) cell lines. Compound 3 exhibited potent inhibitory activity and good selectivity margin. Compounds 2, 3, and 7 exerted apoptotic effect in MCF7 cells in a dose-dependent manner. The cytotoxicity of the verified compounds was inferior to that of podophyllotoxin.